High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides
暂无分享,去创建一个
R. L. Juliano | W. Janzen | R. Juliano | X. Ming | A. Yuan | M. Suto | E. Hull-Ryde | B. Yang | X. Ming | C. Cao | B. Laing | A. Yuan | M. A. Porter | E. A. Hull-Ryde | J. Maddry | M. Suto | W. P. Janzen | Melissa A. Porter | J. Maddry | M. Porter | B. Laing | Canhong Cao | C. Cao | B. Yang | B. Yang | B. Yang | Xin Ming | Bing Yang
[1] K. G. Rajeev,et al. Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. , 2011, Bioconjugate chemistry.
[2] P. Boisguérin,et al. Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells , 2013, Nucleic acids research.
[3] V. Haucke,et al. At the Crossroads of Chemistry and Cell Biology: Inhibiting Membrane Traffic by Small Molecules , 2012, Traffic.
[4] L. Johannes,et al. Inhibition of Retrograde Transport Protects Mice from Lethal Ricin Challenge , 2010, Cell.
[5] Man Tsuey Tse. Regulatory watch: Antisense approval provides boost to the field , 2013, Nature Reviews Drug Discovery.
[6] R. Juliano,et al. Conjugation with receptor-targeted histidine-rich peptides enhances the pharmacological effectiveness of antisense oligonucleotides. , 2014, Bioconjugate chemistry.
[7] X. Ming,et al. Transport of Dicationic Drugs Pentamidine and Furamidine by Human Organic Cation Transporters , 2009, Drug Metabolism and Disposition.
[8] K. G. Rajeev,et al. Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] A. Krainer,et al. RNA therapeutics: beyond RNA interference and antisense oligonucleotides , 2012, Nature Reviews Drug Discovery.
[10] J. Wengel,et al. Locked vs. Unlocked Nucleic Acids (LNA vs. UNA): Contrasting Structures Work Towards Common Therapeutic Goals , 2012 .
[11] R. Juliano,et al. Biological barriers to therapy with antisense and siRNA oligonucleotides. , 2009, Molecular pharmaceutics.
[12] H. Maeda,et al. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.
[13] Chantal Pichon,et al. Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers , 2009, British journal of pharmacology.
[14] Daniel G. Anderson,et al. Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.
[15] B. Bettencourt,et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. , 2013, The New England journal of medicine.
[16] H. Cai,et al. Coats, tethers, Rabs, and SNAREs work together to mediate the intracellular destination of a transport vesicle. , 2007, Developmental cell.
[17] V. Torchilin,et al. siRNA delivery: from basics to therapeutic applications. , 2013, Frontiers in bioscience.
[18] Xiaoyuan Chen,et al. Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor , 2010, Nucleic acids research.
[19] D. Oupický,et al. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[20] George A. Calin,et al. RNAi Therapies: Drugging the Undruggable , 2014, Science Translational Medicine.
[21] H. Scher,et al. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer , 2013, British Journal of Cancer.
[22] S. Pfeffer. Rab GTPase regulation of membrane identity. , 2013, Current opinion in cell biology.
[23] R. Kole,et al. Anti-tumor activity of splice-switching oligonucleotides , 2010, Nucleic acids research.
[24] Anton P. McCaffrey,et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.
[25] Dmitri Kireev,et al. Identification of non-peptide malignant brain tumor (MBT) repeat antagonists by virtual screening of commercially available compounds. , 2010, Journal of medicinal chemistry.
[26] J. Maddry,et al. Antimycobacterial activity of 1-deaza-7,8-dihydropteridine derivatives against Mycobacterium tuberculosis and Mycobacterium avium complex in vitro. , 2001, The Journal of antimicrobial chemotherapy.
[27] J. Cintrat,et al. The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides , 2013, Nucleic acids research.
[28] Shimeng Liu,et al. Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. , 2014, Nanomedicine.
[29] L. Johannes,et al. Retrograde Transport: Two (or More) Roads Diverged in an Endosomal Tree? , 2011, Traffic.
[30] J. Wengel,et al. Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. , 2011, Chemical Society reviews.
[31] Xiaoyuan Chen,et al. Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis , 2008, Nucleic acids research.
[32] X. Ming,et al. Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides. , 2013, Biomaterials.
[33] H. McMahon,et al. Mechanisms of endocytosis. , 2009, Annual review of biochemistry.
[34] Ű. Langel,et al. Molecular parameters of siRNA--cell penetrating peptide nanocomplexes for efficient cellular delivery. , 2013, ACS nano.
[35] P. Herdewijn,et al. Inhibition of MDR1 expression with altritol-modified siRNAs , 2007, Nucleic acids research.
[36] R. Juliano,et al. Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. , 2012, Bioconjugate chemistry.
[37] Tim J. Wigle,et al. Screening for Inhibitors of Low-Affinity Epigenetic Peptide-Protein Interactions: An AlphaScreen™-Based Assay for Antagonists of Methyl-Lysine Binding Proteins , 2010, Journal of biomolecular screening.
[38] Vadim Zinchuk,et al. Quantitative Colocalization Analysis of Confocal Fluorescence Microscopy Images , 2008, Current protocols in cell biology.
[39] Juliane Nguyen,et al. Nucleic acid delivery: the missing pieces of the puzzle? , 2012, Accounts of chemical research.
[40] Y. Nagasaki,et al. Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles. , 2010, Nanomedicine.
[41] Hua Yu,et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.
[42] C. Tyler-Smith,et al. Attenuation of green fluorescent protein half-life in mammalian cells. , 1999, Protein engineering.
[43] E. Wickstrom,et al. Fluorescent peptide-PNA chimeras for imaging monoamine oxidase A mRNA in neuronal cells. , 2012, Bioconjugate chemistry.
[44] M. Egli,et al. Structure and nuclease resistance of 2',4'-constrained 2'-O-methoxyethyl (cMOE) and 2'-O-ethyl (cEt) modified DNAs. , 2012, Chemical communications.
[45] Sarah Seifert,et al. Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape , 2013, Nature Biotechnology.
[46] J. Gruenberg,et al. Lipid sorting and multivesicular endosome biogenesis. , 2013, Cold Spring Harbor perspectives in biology.
[47] Annick Thomas,et al. Self-assembling peptide-based nanoparticles for siRNA delivery in primary cell lines. , 2012, Small.
[48] S. Akhtar. Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics , 2010, Expert opinion on drug metabolism & toxicology.
[49] J. Kjems,et al. Advances in targeted delivery of small interfering RNA using simple bioconjugates , 2014, Expert opinion on drug delivery.
[50] William P. Janzen,et al. Development of a High-Throughput Assay for Identifying Inhibitors of TBK1 and IKKε , 2012, PloS one.
[51] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.
[52] Scott D Emr,et al. The ESCRT pathway. , 2011, Developmental cell.
[53] Eliza J. R. Peterson,et al. High-throughput screening for RecA inhibitors using a transcreener adenosine 5'-O-diphosphate assay. , 2012, Assay and drug development technologies.
[54] A. Helwak,et al. High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells , 2006, PLoS biology.
[55] Olga Zinchuk,et al. Quantitative Colocalization Analysis of Confocal Fluorescence Microscopy , 2008 .
[56] Gert Storm,et al. Endosomal escape pathways for delivery of biologicals. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[57] L. O’Neill,et al. Biochemical regulation of the inflammasome , 2012, Critical reviews in biochemistry and molecular biology.
[58] M. Manoharan,et al. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes , 2011, Nucleic acids research.
[59] Kenneth W Dunn,et al. A practical guide to evaluating colocalization in biological microscopy. , 2011, American journal of physiology. Cell physiology.
[60] D. Corey,et al. Silencing disease genes in the laboratory and the clinic , 2012, The Journal of pathology.
[61] Xiaoyuan Chen,et al. The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. , 2010, Oligonucleotides.
[62] C. Bennett,et al. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. , 2010, Annual review of pharmacology and toxicology.
[63] Shi Xu,et al. Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. , 2013, Advanced drug delivery reviews.
[64] Leaf Huang,et al. Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. , 2010, Journal of the American Chemical Society.
[65] S. Emr,et al. A Nobel Prize for membrane traffic: Vesicles find their journey’s end , 2013, The Journal of cell biology.
[66] Daniel Anderson,et al. Delivery materials for siRNA therapeutics. , 2013, Nature materials.
[67] J. Burnett,et al. RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.
[68] R. Kole,et al. Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[69] Federica Gemignani,et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues , 2002, Nature Biotechnology.
[70] G. Sczakiel,et al. Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: novel options by phosphorothioate-stimulated delivery , 2007, Expert opinion on biological therapy.
[71] Leaf Huang,et al. Targeted delivery of RNAi therapeutics for cancer therapy. , 2010, Nanomedicine.
[72] M. Wood,et al. Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. , 2013, Human gene therapy.